Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:TLRY NASDAQ:WVE NASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.64+1.2%$5.23$3.21▼$7.18$1.60B0.744.65 million shs2.67 million shsTLRYTilray Brands$1.09-4.4%$0.87$0.35▼$1.88$1.20B2.0142.85 million shs37.65 million shsWVEWAVE Life Sciences$7.39-1.2%$8.47$5.28▼$16.74$1.18B-1.151.43 million shs2.31 million shsYMABY-mAbs Therapeutics$8.58$6.58$3.55▼$16.11$389.86M0.53536,586 shs655,208 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-0.46%+2.50%+25.91%+77.30%+15.29%TLRYTilray Brands+1.79%-8.80%+75.74%+167.73%-32.94%WVEWAVE Life Sciences-1.32%-22.25%-7.54%+4.03%+25.08%YMABY-mAbs Therapeutics-0.12%+0.23%+0.82%+74.04%-35.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.64+1.2%$5.23$3.21▼$7.18$1.60B0.744.65 million shs2.67 million shsTLRYTilray Brands$1.09-4.4%$0.87$0.35▼$1.88$1.20B2.0142.85 million shs37.65 million shsWVEWAVE Life Sciences$7.39-1.2%$8.47$5.28▼$16.74$1.18B-1.151.43 million shs2.31 million shsYMABY-mAbs Therapeutics$8.58$6.58$3.55▼$16.11$389.86M0.53536,586 shs655,208 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-0.46%+2.50%+25.91%+77.30%+15.29%TLRYTilray Brands+1.79%-8.80%+75.74%+167.73%-32.94%WVEWAVE Life Sciences-1.32%-22.25%-7.54%+4.03%+25.08%YMABY-mAbs Therapeutics-0.12%+0.23%+0.82%+74.04%-35.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.10Buy$11.7076.20% UpsideTLRYTilray Brands 2.33Hold$1.9477.75% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.33175.15% UpsideYMABY-mAbs Therapeutics 1.80Reduce$9.6212.15% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, ARDX, WVE, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025WVEWAVE Life SciencesB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/4/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.009/3/2025WVEWAVE Life SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.009/3/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$14.009/3/2025WVEWAVE Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.009/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy8/25/2025TLRYTilray BrandsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.50 ➝ $2.008/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$8.00 ➝ $9.008/6/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$11.00 ➝ $8.608/5/2025YMABY-mAbs TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$8.608/5/2025YMABY-mAbs TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$26.00 ➝ $8.60(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M4.80N/AN/A$0.73 per share9.10TLRYTilray Brands$210.48M5.70$0.14 per share7.75$1.40 per share0.78WVEWAVE Life Sciences$108.30M10.86N/AN/A$1.37 per share5.39YMABY-mAbs Therapeutics$85.39M4.57N/AN/A$2.05 per share4.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A21.42N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)TLRYTilray Brands-$2.19B-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%11/14/2025 (Estimated)Latest YMAB, ARDX, WVE, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025YMABY-mAbs Therapeutics-$0.27-$0.07+$0.20-$0.07$18.40 million$19.52 million8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 million7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03TLRYTilray Brands0.202.461.49WVEWAVE Life SciencesN/A2.562.56YMABY-mAbs TherapeuticsN/A4.003.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%TLRYTilray Brands9.35%WVEWAVE Life Sciences89.73%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%TLRYTilray Brands0.60%WVEWAVE Life Sciences23.98%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableYMABY-mAbs Therapeutics15045.44 million36.49 millionOptionableYMAB, ARDX, WVE, and TLRY HeadlinesRecent News About These CompaniesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateSeptember 9 at 2:53 AM | marketbeat.comY-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma TreatmentSeptember 7 at 8:16 PM | msn.com112,483 Shares in Y-mAbs Therapeutics, Inc. $YMAB Acquired by Nuveen LLCSeptember 7 at 3:13 AM | marketbeat.comY-mAbs Therapeutics, Inc. $YMAB Shares Bought by Wellington Management Group LLPSeptember 2, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?September 1, 2025 | zacks.comY-mAbs Therapeutics, Inc. $YMAB Stake Lifted by Acorn Capital Advisors LLCSeptember 1, 2025 | marketbeat.comStonepine Capital Management LLC Acquires New Stake in Y-mAbs Therapeutics, Inc. $YMABAugust 26, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Reduce" from AnalystsAugust 25, 2025 | marketbeat.comY-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 19, 2025 | globenewswire.comAcquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics StockAugust 13, 2025 | insidermonkey.comY-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comXTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)August 10, 2025 | marketbeat.comA Look Ahead: Y-mAbs Therapeutics's Earnings ForecastAugust 9, 2025 | benzinga.comY-mAbs (YMAB) Q2 Revenue Falls 14%August 9, 2025 | aol.comAY-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2025 | zacks.comShareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersAugust 8, 2025 | businesswire.comY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 8, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)August 7, 2025 | prnewswire.comY-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 7, 2025 | businesswire.comY-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings CallAugust 7, 2025 | quiverquant.comQY-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025August 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Tilray's High Hopes: The Catalyst Driving Cannabis StocksBy Jeffrey Neal Johnson | August 21, 2025YMAB, ARDX, WVE, and TLRY Company DescriptionsArdelyx NASDAQ:ARDX$6.64 +0.08 (+1.22%) Closing price 04:00 PM EasternExtended Trading$6.60 -0.04 (-0.54%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Tilray Brands NASDAQ:TLRY$1.09 -0.05 (-4.39%) Closing price 04:00 PM EasternExtended Trading$1.08 -0.02 (-1.38%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.WAVE Life Sciences NASDAQ:WVE$7.39 -0.09 (-1.20%) Closing price 04:00 PM EasternExtended Trading$7.38 -0.01 (-0.20%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Y-mAbs Therapeutics NASDAQ:YMAB$8.58 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$8.58 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
